Pain

>

Latest News

Suzetrigine Phase 3 Data Presented During "Best Abstract" Session at Anesthesiologists' Annual Meeting / image credit postop concept: ©Justlight AI/stock.adobe.com
Vertex Presents Phase 3 Data on Nonopioid Suzetrigine to Treat Acute Pain at Anesthesiologists' Annual Meeting

October 21st 2024

The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.

Depression, Anxiety in Youth with Chronic Pain: Daily Dose / image credit: ©New Africa/AdobeStock
Depression, Anxiety in Youth with Chronic Pain: Daily Dose

October 15th 2024

Youth with Chronic Pain Face Greater Symptoms of Depression, Anxiety than Pain-Free Peers / Image credit: ©New Africa/AdobeStock
Youth with Chronic Pain Face Greater Symptoms of Depression, Anxiety than Pain-Free Peers

October 2nd 2024

High Percentage of Patients Seek Mental Health Care from PCPs, According to New Large Analysis / Image credit: ©DragonImages/AdobeStock
High Percentage of Patients Seek Mental Health Care from PCPs, According to New Large Analysis

September 23rd 2024

FDA Accepts Vertex NDA for Suzetrigine, Investigational Oral Nonopioid Analgesic for Acute pain / Image credit Justlight/stock.adobe.com via AI
FDA Accepts Vertex NDA for Suzetrigine, Investigational Oral Nonopioid Analgesic for Acute pain

August 15th 2024

Latest CME Events & Activities

Mastering MS: Translating Evidence into Optimal Management Plans

View More

Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care

View More

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis - Current Treatment and Emerging Con...

November 12, 2024

Register Now!

Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes

View More

2024 Neuromuscular Summit

November 20, 2024

View More

5th Annual International Congress on the Future of Neurology®

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors

View More

Burst CME: Optimizing Therapy in Parkinson’s Disease

View More

Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders

View More

Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients

View More

Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders

View More

Individualizing Treatment for Patients with Generalized Myasthenia Gravis

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care

View More

Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations

View More

BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders

View More

BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis

View More

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions

View More

Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis

View More

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

More News

© 2024 MJH Life Sciences

All rights reserved.